Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Since many individuals with type 2 diabetes appear to have an inadequacy or defect in one or both of these processes, identifying compounds that can activate GK could provide a therapeutic benefit.
|
31818630 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Islet ATAC-seq peaks overlap with 13 SNPs associated with T2D (e.g. rs7903146, rs2237897, rs757209, rs11708067 and rs878521 near TCF7L2, KCNQ1, HNF1B, ADCY5 and GCK, respectively) and with additional 67 SNPs in LD with known T2D SNPs (e.g.
|
31123324 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
The clinical characteristics of patients with GK-activating mutations or GK regulatory protein (GKRP) loss-of-function mutations suggest that a hepatoselective GK activator (GKA) that does not activate GK in β cells or affect the GK-GKRP interaction may reduce hyperglycemia in patients with type 2 diabetes while limiting hypoglycemia and liver-associated adverse effects.
|
30651321 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
TTP399 is a hepatoselective, glucokinase activator with potential for treating type 2 diabetes.
|
31398075 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, 200 and 500 mg kg-1 d-1 ARs significantly increased the content of hepatic glycogen and the activity of glucokinase (p < 0.01) in T2DM mice.
|
31094396 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
The N-pyridin-2-yl benzamide analogues discovered in the current study can provide some lead molecules for the development of potent oral GK activators with minimum side-effects for the management of type 2 diabetes.
|
30369030 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
To estimate the prevalence of glucokinase variant-induced diabetes (GCK-DM) in a general population and to establish a clinical strategy for identifying GCK-DM from type 2 diabetes (T2DM).
|
30245511 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
The APOE<sup>∗</sup>3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis.
|
30949516 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We have previously identified a mutant GK (R308K) in patients with type 2 diabetes with reduced enzyme activity.
|
30087826 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Allosteric activators of GK (GKAs) have the potential to treat type 2 diabetes mellitus.
|
30006171 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
The effect of arc GK was maintained in a model of type 2 diabetes.
|
29748994 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Adult-onset, or type II diabetes mellitus (T2DM) has a complex genetic architecture, from hundreds of genes with low penetrance, common susceptibility variants (e.g., TCF7L2), to a set of more than ten genes that, when mutated, can cause a single-gene or Mendelian form of T2DM (e.g., GCK).
|
29458357 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
To investigate the pharmacokinetics and pharmacodynamics of a dual-acting glucokinase activator, dorzagliatin, and its safety, tolerability and effect on pancreatic β-cell function in Chinese patients with type 2 diabetes (T2D).
|
29707866 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
In participants with GCK-MODY, treatment cessation was universally successful, with no change in HbA<sub>1c</sub> at follow-up.
|
30229274 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
It is demonstrated for the first time that dietary ANC can enhance the activity of novel biomarkers FFAR1 and GK and potentially ameliorate type-2 diabetes comorbidities.
|
29995924 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
These newly synthesized thiazol-2-yl benzamide derivatives thus can be treated as the initial hits for the development of new, safe, effective and orally bioavailable GK activators as therapeutic agents for the treatment of type 2 diabetes.
|
29518630 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to investigate differences in serum miR-122 levels in Chinese patients with different forms of diabetes, including T2DM, type 1 diabetes (T1DM), HNF1A variant-induced diabetes (HNF1A-DM), glucokinase variant-induced diabetes (GCK-DM), and mitochondrial A3243G mutation-induced diabetes (MDM).
|
30155490 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Most (6/7) patients with HNF4A variants rapidly failed TODAY treatment across study arms (hazard ratio = 5.03, P = 0.0002), while none with GCK variants failed treatment.ConclusionThe finding of 4.5% of patients with monogenic diabetes in an overweight/obese cohort of children and adolescents with T2D suggests that monogenic diabetes diagnosis should be considered in children and adolescents without diabetes-associated autoantibodies and maintained C-peptide, regardless of BMI, as it may direct appropriate clinical management.
|
29758564 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
This case highlights the value of sequencing the GCK gene in individuals with GCK-MODY phenotype and no family history of monogenic diabetes.
|
30086370 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glucokinase activators had been reported as one kind of new potential drugs for treatment of type 2 diabetes.
|
29477658 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Here, we analyze human islets from individuals without or with T2D, using TaqMan-based real-time qPCR at the tissue (isolated islet) level as well as at single cell resolution, to assess the relationship between miR-206 and GCK expression in normal and T2D human islets.
|
29989852 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Maturity onset diabetes type 2 [MODY2 (#125851)] caused by mutations in the glucokinase gene (GCK).
|
29056535 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Heterozygous inactivating mutations in GCK are associated with defects in pancreatic insulin secretion and/or hepatic glycogen synthesis leading to mild chronic hyperglycaemia of maturity onset diabetes of young type 2 (MODY2).
|
30257192 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Although the influence of a common variant in the glucokinase regulatory gene (GCKR rs780094) in type 2 diabetes mellitus has been well documented, less data however, is available of its role in gestational diabetes mellitus (GDM).
|
29410004 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Author Correction: Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus.
|
29670171 |
2018 |